The present invention relates to the use of a compound selected from the group consisting of cystuffrin compounds, in vivo hydrolysable precursors thereof or pharmaceutically acceptable salts thereof, and nonsteroidal insulin compounds, diabetic complications (diabetic renal insufficiency and foot ulceration) The prophylactic and therapeutic efficacy against cardiovascular diseases such as sex, non-alcoholic and viral fatty liver disease, obesity, hyperlipidemia, atherosclerosis, arteriosclerosis, brain diseases (Parkinson's disease, manic depression, schizophrenia and Alzheimer's disease) . The present invention also relates to the provision of compositions of functional foods, functional beverages, functional cosmetics and functional feeds of these substances. The cystafin compound of the present invention has an excellent effect in preventing and treating cardiovascular diseases such as hyperlipidemia and arteriosclerosis in addition to diabetes and fatty liver and obesity. In addition, low-density lipoprotein cholesterol (LDL) reduction and macrophage-derived inflammatory cytokines and lipid biosynthetic enzymes are inhibited in the liver to prevent and treat hyperlipidemia, atherosclerosis and cardiovascular diseases with a combination of existing nuclear receptor LXR agonists . Furthermore, it activates proteins involved in dopamine homeostasis of neurons, and can be used as a preventive treatment for Parkinson's disease, bipolar disorder and schizophrenia as a single agent. The compound of the present invention can be used as a prophylactic and therapeutic agent for Alzheimer's disease as a combination with nuclear receptor LXR agonists reported in the literature that is known to have an effect of preventing and treating Alzheimer's disease by inhibiting fatty liver which is a side effect of existing LXR active substance have. In addition, it can be used as a preventive and therapeutic agent for brain diseases such as Parkinson's disease and dementia in addit
